These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3402355)

  • 1. Efficacy of once-daily urapidil treatment in mild or moderate essential hypertension assessed by ambulatory 24-hour blood pressure monitoring.
    Trimarco B; Rosiello G; Feldhaus P; Steinijans VW; Vecchione F; Cuocolo A; Lembo G; Volpe M
    Drugs; 1988; 35 Suppl 6():173-81. PubMed ID: 3402355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of urapidil and atenolol in hypertension.
    Török E; Wagner M; Podmaniczky M
    Drugs; 1988; 35 Suppl 6():164-72. PubMed ID: 3042356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antihypertensive effect of urapidil in mild to moderate arterial hypertension. Randomized, double-blind versus placebo study].
    Amodeo C; Barros LM; Batlouni M; Sousa JE
    Arq Bras Cardiol; 1993 Aug; 61(2):127-30. PubMed ID: 8297222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical aspects of antihypertensive therapy with urapidil. Comparison with hydrochlorothiazide.
    Distler A; Haerlin R; Hilgenstock G; Passfall J
    Drugs; 1990; 40 Suppl 4():21-7; discussion 28-30. PubMed ID: 2092965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind comparison of urapidil and prazosin in the treatment of patients with essential hypertension.
    Kaneko Y
    Drugs; 1988; 35 Suppl 6():156-63. PubMed ID: 3042355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive effects of urapidil and clonidine: a double-blind cross-over study.
    Kanniainen E; Heikkilä O; Jääskeläinen T; Lilja M; Jounela AJ
    Eur J Clin Pharmacol; 1985; 28(1):35-9. PubMed ID: 3886400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic assessment of urapidil or angiotensin-converting enzyme inhibition in systemic hypertension.
    Rosenthal J; Haerlin R
    Am J Cardiol; 1989 Aug; 64(7):25D-29D. PubMed ID: 2667311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of urapidil in the management of essential hypertension. A comparison with captopril.
    Rosenthal J; Haerlin R; Schäfer N; Christ B; Wurst W
    Drugs; 1988; 35 Suppl 6():147-55. PubMed ID: 3042354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension.
    Graney WF
    Am J Med; 1992 Aug; 93(2A):56S-64S. PubMed ID: 1519637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of mild hypertension with urapidil or captopril.
    Rosenthal J; Schäfer N; Haerlin R; Wurst W; Solleder P
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):233S-236S. PubMed ID: 3046630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of urapidil, a new antihypertensive drug: preliminary findings in Japan.
    Taniguchi K; Nakamura S; Iesaka Y; Nitta M; Ito H; Kirigaya H; Takeuchi J; Fujiwara H; Iizumi T; Inada M
    Clin Ther; 1985; 7(5):559-67. PubMed ID: 4053145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of clinical trials with urapidil.
    Schook CE; Radtke H; Wurst W; Thieme G
    Am J Cardiol; 1989 Aug; 64(7):30D-37D. PubMed ID: 2667312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.
    Zanchetti A
    Blood Press Suppl; 1995; 3():38-46. PubMed ID: 8535541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Course of blood pressure within the first 12 h of hypertensive urgencies.
    Hirschl MM; Herkner H; Bur A; Woisetschläger C; Gamper G; Frossard M; Laggner AN
    J Hypertens; 1998 Feb; 16(2):251-5. PubMed ID: 9535154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B; Gerwe M; Braun M; Funken C
    Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of systemic arterial hypertension with urapidil. Study in mild and moderate hypertension with ambulatory monitoring of arterial pressure].
    Nobre F; Nogueira JL
    Arq Bras Cardiol; 1993 Jul; 61(1):63-8. PubMed ID: 8285870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antihypertensive effect and tolerance to urapidil. Comparison with nifedipine in a multicenter double-blind study].
    Stumpe KO; Feldhaus P; Haerlin R
    Fortschr Med; 1989 Jan; 107(1):54-7. PubMed ID: 2646188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved orthostatic dysregulation record after administration of a sustained-release form of urapidil.
    Kirsten R; Nelson K; Kirch W; Hutt HJ; Molz KH; Theodor R; Nieder M; Dilger C; Haerlin R; Wurst W
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):338-41. PubMed ID: 2777422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.